Overview
PMS to Evaluate the Safety and Efficacy of Picato® Gel
Status:
Completed
Completed
Trial end date:
2018-01-19
2018-01-19
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is a mandatory post launch observational study in South Korea of 3.000 patients receiving treatment for the first time with a new medicinal product, ingenol mebutate gel (Picato®), approved for topical treatment of actinic keratosis. Each patient is observed for 8 weeks after treatment completion.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
LEO Pharma
Criteria
Inclusion Criteria:Adult patient with AK First time treatment with ingenol mebutate 0.015 or 0.05 percent gel
Exclusion Criteria:
- Children and adolescents